ProMIS Neurosciences is trading 5.03% down in pre-market at $14.16, with no fresh company-specific announcement found for August 21, 2026.
- The latest identified company news was August 13, 2026, when ProMIS reported positive blinded safety and biomarker data alongside second-quarter results.
- Broader equities are modestly higher pre-market, so the decline cannot be clearly attributed to market-wide weakness.
- Trading activity and volume details were unavailable, leaving the immediate catalyst uncertain.